Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint Inhibitors

Patent metadata

Field	Value
Publication number	US-2022267445-A1
Application number	US-202217673602-A
Country	US
Kind code	A1
Filing date	Feb 16, 2022
Priority date	Feb 17, 2021
Publication date	Aug 25, 2022
Grant date	—

Abstract

Methods and kits treating a subject with a checkpoint inhibitor are provided by detecting expression levels of one or more biomarkers (e.g., cytokines and cytotoxic genes, immune cell functional regulators, naïve immune cell markers, regulatory T cell factors, and immune inhibitory receptors) in immune cells of a patient or subject with a condition (e.g., cancer) before and after exposure of tumor cells to alternating electric fields. Kits comprising nucleic acid probes for detecting the one or more biomarkers are also provided.

First claim

1 . A method, comprising:
(a) determining in immune cells of a subject a first expression level of the following biomarker(s):
cytokines and cytotoxic genes,
immune cell functional regulators,
naïve immune cell markers,
regulatory T cell factors, or
immune inhibitory receptors, or
combinations thereof;
(b) applying alternating electric fields to tumor cells of the subject at a frequency between 50 kHz-1 MHz after step (a) and prior to step (c); and (c) determining in immune cells of the subject a second expression level of the biomarker(s) of step (a).

2 . The method of claim 1 , wherein the frequency is between 100 kHz and 500 kHz.

3 . The method of claim 1 , wherein step (a) comprises determining a first expression level of cytokines and cytotoxic genes.

4 . The method of claim 1 , wherein step (a) comprises determining a first expression level of immune cell functional regulators.

5 . The method of claim 1 , wherein step (a) comprises determining a first expression level of cytokines and cytotoxic genes, and determining a first expression level of immune cell functional regulators.

6 . The method of claim 4 , wherein the immune cell functional regulators are T cell functional regulators.

7 . The method of claim 1 , wherein step (a) comprises determining a first expression level of:
cytokines and cytotoxic genes, immune cell functional regulators, naïve immune cell markers, regulatory T cell factors, and immune inhibitory receptors.

8 . The method of claim 1 , wherein
biomarker expression level is determined by nucleic acid expression or by expression of a corresponding protein.

9 . The method of claim 1 , further comprising treating the subject with a checkpoint inhibitor if:
(i) the first expression level of at least 50% of the cytokines and cytotoxic genes is lower than the second expression level of cytokines and cytotoxic genes, (ii) the first expression level of at least 50% of the immune cell functional regulators is lower than the second expression level of immune cell functional regulators, (iii) the first expression level of at least 50% of the naïve immune cell markers is greater than the second expression level of naïve immune cell markers, (iv) the first expression level of at least 50% of the regulatory T cell factors is greater than the second expression level of regulatory T cell factors, or (v) the first expression level of at least 50% of the immune inhibitory receptors is either greater than or unchanged compared to the second expression level of immune inhibitory receptors.

10 . The method of claim 9 , further comprising treating the subject with a checkpoint inhibitor if the first expression level of at least 50% of the cytokines and cytotoxic genes is lower than the second expression level of cytokines and cytotoxic genes.

11 . The method of claim 9 , further comprising treating the subject with a checkpoint inhibitor if the first expression level of at least 50% of the immune cell functional regulators is lower than the second expression level of immune cell functional regulators.

12 . The method of claim 9 , further comprising treating the subject with a checkpoint inhibitor if:
(i) the first expression level of at least 50% of the cytokines and cytotoxic genes is lower than the second expression level of cytokines and cytotoxic genes, and (ii) the first expression level of at least 50% of the immune cell functional regulators is lower than the second expression level of immune cell functional regulators.

13 . The method of claim 1 , wherein the immune cell functional regulators are T cell functional regulators or the naïve immune cell markers are naïve T cell markers.

14 . The method of claim 1 , wherein the nucleic acids expressing cytokines and cytotoxic gene are selected from the group consisting of GZMB, GZMH, GZMK, GNLY, PRF1, INFG, NKG7, CX3CR1, CCL3, and CCL4, and combinations thereof.

15 . The method of claim 1 , wherein the nucleic acids expressing immune cell functional regulators are selected from the group consisting of ZEB2, ZHF683, HOPX, TBX21, ID2, TOX, GF11, EOMES, and HMGB3, and combinations thereof.

16 . (canceled)

17 . (canceled)

18 . (canceled)

19 . (canceled)

20 . The method of claim 9 , wherein the checkpoint inhibitor is selected from the group consisting of ipilimumab, pembrolizumab, nivolumab, cemilimab, atezolimumab, avelumab, durvalumab, IDO1 inhibitors, TIGIT inhibitors, LAG-3 inhibitors, TIM-3 inhibitors, VISTA inhibitors, and B7-H3 inhibitors.

21 . The method of claim 1 , wherein the tumor cells are selected from the group consisting of brain cells, blood cells, breast cells, pancreatic cells, ovarian cells, lung cells, and mesenchymal cells.

22 . The method of claim 21 , wherein the tumor cells are brain cells.

23 . The method of claim 21 , wherein the tumor cells are cancer cells.

24 . A kit comprising nucleic acids for detecting expression of cytokines and cytotoxic genes, nucleic acids expressing T cell functional regulators, nucleic acids expressing naïve T cell markers, nucleic acids expressing regulatory T cell factors, and nucleic acids expressing immune inhibitory receptors.

25 . The kit of claim 24 , wherein the nucleic acids expressing cytokines and cytotoxic genes are selected from the group consisting of GZMB, GZMH, GZMK, GNLY, PRF1, INFG, NKG7, CX3CR1, CCL3, and CCL4, and combinations thereof, and the nucleic acids expressing immune cell functional regulators are selected from the group consisting of ZEB2, ZHF683, HOPX, TBX21, ID2, TOX, GF11, EOMES, and HMGB3, and combinations thereof.

26 . (canceled)

27 . (canceled)

28 . (canceled)

29 . (canceled)

30 . (canceled)

Assignees

• Novocure Gmbh

Inventors

• Tran David
• Chen Dongjiang

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C12Q2600/158

  Expression markers · CPC title

• A61P35/00

  Antineoplastic agents · CPC title